Twenty-five percent and 35% of ET and PMF patients, respectively, had mutations in CALR. All patients with mutated CALR had non-mutated JAK2 and MPL (CALR mutations are mutually exclusive with mutations in both JAK2 and MPL). Here, CALR is linked to essential thrombocythemia.